A Surprising New Hope for Nasal Polyps: Why Doctors Are Expanding Treatment Beyond Surgery

For decades, doctors have relied on a simple rule: if you have nasal polyps, you might benefit from biologic therapy. But a groundbreaking real-world study is upending that assumption, showing that a targeted anti-inflammatory drug works remarkably well for patients who don't have visible polyps at all—opening doors for millions of people who've been left out of treatment conversations.

What Changed in How Doctors Treat Nasal Polyps?

For years, the presence or absence of nasal polyps determined everything about treatment strategy. Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) got access to newer biologic drugs, while those without visible polyps (CRSsNP) were largely stuck with older treatments like nasal sprays and surgery. The thinking was straightforward: polyps meant type-2 inflammation, the kind these drugs target. No polyps meant you probably didn't need them.

Researchers at Mayo Clinic decided to test this assumption in the real world. They tracked 277 patients with chronic rhinosinusitis who received mepolizumab, a drug that blocks interleukin-5 (IL-5), a key protein driving eosinophilic inflammation. What they found was striking: the drug worked across both groups, regardless of whether patients had visible polyps.

How Well Did the Treatment Actually Work?

The results were significant on multiple fronts. Mepolizumab reduced serum eosinophil counts—a marker of inflammation in the blood—from a median of 0.57 to 0.07 (measured in billions of cells per liter), a reduction with high certainty of being real and meaningful. CT scan scores, which measure disease burden in the sinuses, also improved significantly, dropping from a median of 14 to 10 points.

What's particularly important is that these improvements held steady across all patient subgroups—whether someone had visible polyps or not, and whether they'd had previous sinus surgery or were coming to biologic therapy for the first time. The consistency of these findings suggests that the drug's mechanism of action—blocking the inflammatory pathway—matters more than the visible presentation of the disease.

However, symptom improvement was more variable. While some patients reported significant relief from congestion, facial pressure, and drainage, others saw only modest gains. This heterogeneity highlights something doctors are increasingly recognizing: chronic sinus disease is more complex than it appears on the surface, and different patients respond differently even when they receive the same treatment.

Why Does This Matter for Patients Without Visible Polyps?

The study revealed that approximately 30% of the patient population had chronic rhinosinusitis without nasal polyps (CRSsNP), yet many of these patients showed the same type-2 inflammatory profile as those with polyps. This finding is crucial because it suggests that up to 55% of CRSsNP patients may have underlying type-2 inflammation that responds to IL-5 blockade, even though they wouldn't traditionally qualify for biologic therapy based on appearance alone.

"Emerging evidence suggests that immunologic endotypes may better predict response to targeted biologic therapies than phenotypes alone," the research team noted, explaining that what you see on examination may not tell the whole story about what's driving a patient's disease.

Steps to Understanding Your Treatment Options

• Ask About Inflammatory Testing: If you have chronic sinus symptoms that aren't improving with standard treatments, ask your doctor about testing for eosinophilic inflammation, even if you don't have visible polyps. Blood tests and tissue samples can reveal whether type-2 inflammation is driving your disease.
• Discuss Biologic Eligibility Beyond Polyps: Don't assume you're ineligible for biologic therapy just because you lack visible nasal polyps. The new evidence suggests doctors should consider your inflammatory profile, not just what they see during examination.
• Consider Your Comorbidities: In the study, 93.5% of patients had type-2 inflammatory comorbidities like asthma or eczema. If you have these conditions alongside chronic sinusitis, mention them to your doctor—they strengthen the case for biologic therapy.
• Evaluate Long-Term Commitment: The median duration of mepolizumab therapy in the study was 31 months. Biologic drugs require ongoing treatment, so discuss with your doctor how long you might need therapy and what success looks like for your specific situation.

What About Surgery—Is It Still Necessary?

One interesting finding: patients with visible polyps were more likely to eventually need endoscopic sinus surgery (ESS) during biologic therapy, but the time before needing surgery was longer than for those without polyps. This suggests that while mepolizumab delays or reduces the need for surgery, it doesn't eliminate it for everyone. About 24.9% of patients switched to a different biologic drug, and 16.6% stopped treatment entirely, primarily because their disease didn't respond adequately.

The takeaway: biologic therapy is increasingly seen as a first-line option that can postpone or prevent surgery, rather than a last resort after surgery fails.

The Bigger Picture: A Market Transformation

This shift in how doctors think about nasal polyp treatment is reflected in the broader healthcare market. The nasal polyps treatment market is projected to grow from $5.68 billion in 2025 to $8.9 billion by 2030, expanding at a compound annual growth rate of 9.4%. Much of this growth is driven by increasing adoption of biologic therapies, heightened research into new anti-inflammatory drugs, and growing awareness that chronic sinus disease may benefit from targeted treatment regardless of visible polyp status.

Leading pharmaceutical companies including Regeneron, Sanofi, GlaxoSmithKline, and others are actively pursuing FDA approvals for new treatments. In September 2024, Dupixent (dupilumab) received FDA approval as the first biologic specifically indicated for adolescents aged 12 to 17 with chronic rhinosinusitis and nasal polyps, addressing an unmet need for approximately 9,000 U.S. teenagers.

What Should You Do If You Have Chronic Sinus Problems?

If you've struggled with chronic sinusitis that hasn't responded well to nasal sprays, saline rinses, or antibiotics, the landscape of available treatments has genuinely expanded. The evidence now suggests that your eligibility for newer, more effective therapies shouldn't be determined solely by whether a doctor can see polyps in your nose. Instead, the focus is shifting toward understanding the underlying inflammatory mechanisms driving your disease.

Talk to your doctor about comprehensive evaluation, including blood work to assess eosinophil levels and discussion of your other inflammatory conditions. If you have asthma, eczema, or other type-2 inflammatory diseases alongside your sinus problems, that information is valuable. The goal is moving from a one-size-fits-all approach to personalized medicine based on how your immune system is actually behaving—not just what's visible on the surface.